Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”

The search of predictive biomarkers for immune checkpoint inhibitor (ICIs) therapy remains a topic of major interest in oncology research. Previous studies have suggested that the development of immune-related adverse events (irAEs) can be associated with efficacy of ICIs in different cancer types[1,2,3]. However, statistical caveats such as the immortal-time bias or the publication bias may have overestimated this association[4]. Recently, Kfoury et alhave analysed 577 patients treated with anti-PD-(L)1 antibodies at Gustave Roussy Institute to evaluate the association of irAEs and efficacy outcomes after correctly accounting for immortal-time bias[5].

Source: Cancer Treatment Reviews - September 23, 2022 Category: Cancer & Oncology Authors: Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berch é, Omar Saavedra, David Marmolejo, Oriol Mirallas, Irene Braña, Eva Muñoz-Couselo, Elena Garralda, Rodrigo Dienstmann Tags: Hot Topic Source Type: research